Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers.

RNA (New York, N.Y.) - 17 Aug 2026

Sun Chenyan, Luo Huacheng, Zhang Jing

Abstract excerpt

Mutations in BRCA1 are key drivers of breast cancer by impairing homologous recombination. While these tumors are often sensitive to PARP inhibitors, resistance frequently emerges, highlighting the need to identify additional molecular vulnerabilities. HORMAD1 is frequently overexpressed in triple-negative breast cancer and associated with genomic instability, yet its role in therapy response in BRCA1-deficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to BRCA1 Protein
Share to Cell Cycle Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to RNA-Binding Proteins

Share to RNA Splicing

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 42309673
DOI: 10.1261/rna.081080.126

Genes

BRCA1
HORMAD1
RBM38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers.PMID 42309673Read ↗

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivitySemantic proximity Read ↗

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast CancerSemantic proximity Read ↗

BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.Semantic proximity Read ↗

Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceSemantic proximity Read ↗

Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancerSemantic proximity Read ↗

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Semantic proximity Read ↗

Chromatin signalling pathways and FANCE amplification affect ATR inhibitor sensitivity in metastatic breast cancerSemantic proximity Read ↗

3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.Semantic proximity Read ↗

Development of a novel BRCAness score that predicts response to PARP inhibitorsSemantic proximity Read ↗

Isoform switching as a key mechanism in chemotherapy resistance in triple-negative breast cancerSemantic proximity Read ↗

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitorSemantic proximity Read ↗

IKZF3 amplification frequently occurs in HER2 positive breast cancer and is a potential therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.